Axogen Completes Acquisition of BioCircuit Technologies Adding NerveTape™

ALACHUA, Fla. and TAMPA, Fla., Oct. 01, 2026 /CourierPR/ -- Axogen, a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, has completed its acquisition of BioCircuit Technologies, a privately held medical device company known for its NerveTape™, the first FDA-cleared device for sutureless peripheral nerve repair. This move is significant for Axogen and the medical community, as NerveTape™ represents a new standard of care, offering a simpler, faster, and more effective alternative to microsuturing.

Michael Dale, President and CEO of Axogen, expressed enthusiasm about the acquisition.

NerveTape™ is a groundbreaking product that addresses the everyday need of surgeons to repair nerves. The acquisition is expected to contribute approximately $6 million to Axogen's fourth-quarter 2026 revenue and approximately $34 million to its 2027 revenue. This contribution was not included in Axogen's most recently issued full-year 2026 guidance of at least 24% revenue growth. The Company continues to expect gross margin to be at least 73% and to be free cash positive for the full-year 2026.

BioCircuit Technologies, based in Atlanta, Georgia, specializes in developing and commercializing medical devices for peripheral nerve repair and neuromodulation. Its first commercial product, NerveTape™, is the first FDA-cleared sutureless device for repairing transected nerves. The company has received support from small business funding from the National Institutes of Health and private investment from Alsora Capital, GRA Venture Fund, Michael Masters of Masters Capital Management, and other investors.

Axogen's product portfolio includes Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix®. The acquisition of BioCircuit Technologies is expected to expand Axogen's addressable market and enhance its ability to provide innovative, clinically proven, and economically effective repair solutions for surgeons and healthcare providers.

The integration of NerveTape™ into Axogen's product lineup is anticipated to strengthen the company's position in the peripheral nerve repair market. With the addition of NerveTape™, Axogen aims to improve patient outcomes and simplify the surgical process for nerve repair procedures. The company's full-year 2026 guidance remains unchanged, with expectations of at least 24% revenue growth, a gross margin of at least 73%, and free cash flow.